# Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

> **NCT01813773** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ophthalmic Consultants of Long Island** · enrollment: 20 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Intravitreal Aflibercept Injection (IAI)

## Key facts

- **NCT ID:** NCT01813773
- **Lead sponsor:** Ophthalmic Consultants of Long Island
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813773, "Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01813773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*